Neurology
Page 1 • 4 itemsGain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Alzheimer's Clinical Trial Failures: Insights from Semaglutide & Posdinemab FDA Trials
This article delves into the recent failures of Alzheimer's clinical trials involving Semaglutide and Posdinemab, highlighting key insights and future directions.
Alzheimer's Clinical Trial Failures: Impact of Posdinemab Phase 2 Failure on Drug Development
The Phase 2 failure of Posdinemab raises critical questions about the future of Alzheimer's drug development and the challenges faced in clinical trials.
Alzheimer's Clinical Trial Failures: Impact on US Market & Investment
This article examines the implications of recent Alzheimer's clinical trial failures on the US market and investment trends, focusing on drugs such as Aducanumab.
Alzheimer's Clinical Trial Failures: Novo Nordisk's Semaglutide Phase 3 Outcome & Market Impact
Novo Nordisk's Semaglutide Phase 3 trial for Alzheimer's has failed, raising concerns about future research and market dynamics in neurodegenerative treatments.